Page last updated: 2024-10-30

leflunomide and Glomerulonephritis, Lupus

leflunomide has been researched along with Glomerulonephritis, Lupus in 14 studies

Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.

Research Excerpts

ExcerptRelevanceReference
"Previous studies have compared mycophenolate mofetil and azathioprine as maintenance therapy for lupus nephritis (LN)."9.51Leflunomide versus azathioprine for maintenance therapy of lupus nephritis: a prospective, multicentre, randomised trial and long-term follow-up. ( Bao, C; Dai, L; Dai, M; Fu, Q; He, L; Li, Z; Lu, L; Sun, L; Wang, S; Wu, C; Xu, J; Zhu, X, 2022)
"A prospective, multi-center, randomized controlled study was conducted to evaluate the efficacy and safety of a 24-week course low-dose leflunomide combined with prednisone in the induction treatment of proliferative lupus nephritis in Chinese patients."9.30Leflunomide versus cyclophosphamide in the induction treatment of proliferative lupus nephritis in Chinese patients: a randomized trial. ( Chen, J; Chen, Q; Guan, T; Jiang, G; Li, D; Luo, P; Ni, Z; Qi, C; Sun, M; Sun, Z; Wan, J; Wang, L; Wang, S; Xing, C; Zha, Y; Zhang, M, 2019)
"To evaluate the efficacy and safety of leflunomide in the treatment of proliferative lupus nephritis, a prospective multi-centre observational study was conducted."9.13Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study. ( Cai, GY; Chen, XM; Cui, TG; Hou, FF; Jiang, ZP; Li, YN; Lu, FM; Mei, CL; Ni, ZH; Qian, JQ; Wang, GB; Wang, HY; Wang, YH; Xu, FF; Yu, XQ; Zhang, FS; Zhao, MH; Zhao, XZ; Zhu, TY; Zou, WZ, 2008)
"To evaluate the clinical efficacy and safety of leflunomide as a new immunosuppressive medicine in lupus nephritis (LN) through a meta-analysis."8.91The Efficacy and Safety of Leflunomide for the Treatment of Lupus Nephritis in Chinese Patients: Systematic Review and Meta-Analysis. ( Cao, H; Chen, Z; Lin, J; Liu, L; Rao, Y; Yang, H; Zhang, X, 2015)
" In this model, we evaluated the role of leflunomide on the development of lupus nephritis in system autoimmunity."7.78Therapeutic effect of leflunomide on the development of experimental lupus nephritis in mice. ( He, C; Liu, S; Lu, X; Luo, P; Wu, M; Yan, Z; Yu, Y, 2012)
"To evaluate the clinical and pathological efficacy, and safety of leflunomide as a new immunosuppressive medicine in lupus nephritis (LN)."7.75The efficacy and safety of leflunomide therapy in lupus nephritis by repeat kidney biopsy. ( Jin, XM; Li, YN; Nie, YK; Sun, Y; Yu, HM; Zhang, FS, 2009)
"Leflunomide (LEF) is a selective inhibitor of de novo pyrimidine synthesis, currently used in the treatment of rheumatoid arthritis."6.71[Treatment of proliferative lupus nephritis with leflunomide and steroid: a prospective multi-center controlled clinical trial]. ( Bao, CD; Cai, GY; Chen, XM; Cui, TG; Hou, FF; Li, YN; Lu, FM; Mei, CL; Ni, ZH; Qian, JQ; Wang, GB; Wang, HY; Zhang, FS; Zhao, MH; Zhao, XZ; Zhu, TY; Zou, WZ, 2005)
"The condition of refractory lupus nephritis (LN) negatively affects the prognosis and life expectancy of the patients, posing a challenge to manage in clinical."5.91Treatment of refractory lupus nephritis using leflunomide: A prospective study. ( Chen, X; Chen, Y; Li, M; Wang, L; Zeng, X; Zhang, F; Zhang, S; Zhao, Y, 2023)
"Previous studies have compared mycophenolate mofetil and azathioprine as maintenance therapy for lupus nephritis (LN)."5.51Leflunomide versus azathioprine for maintenance therapy of lupus nephritis: a prospective, multicentre, randomised trial and long-term follow-up. ( Bao, C; Dai, L; Dai, M; Fu, Q; He, L; Li, Z; Lu, L; Sun, L; Wang, S; Wu, C; Xu, J; Zhu, X, 2022)
"A prospective, multi-center, randomized controlled study was conducted to evaluate the efficacy and safety of a 24-week course low-dose leflunomide combined with prednisone in the induction treatment of proliferative lupus nephritis in Chinese patients."5.30Leflunomide versus cyclophosphamide in the induction treatment of proliferative lupus nephritis in Chinese patients: a randomized trial. ( Chen, J; Chen, Q; Guan, T; Jiang, G; Li, D; Luo, P; Ni, Z; Qi, C; Sun, M; Sun, Z; Wan, J; Wang, L; Wang, S; Xing, C; Zha, Y; Zhang, M, 2019)
" A total of 191 lupus nephritis patients were randomized to follow a combined immunosuppressive treatment (CIST) with intravenous cyclophosphamide, an oral immunosuppressive agent, namely mycophenolate mofetil, azathioprine or leflunomide, and hydroxychloroquine (n = 95), or receive intravenous cyclophosphamide alone (n = 96) for 24 weeks."5.30Combined immunosuppressive treatment (CIST) in lupus nephritis: a multicenter, randomized controlled study. ( An, Y; Bi, L; Deng, X; Guo, J; Li, Y; Li, Z; Lin, J; Liu, B; Liu, X; Liu, Y; Lu, X; Mei, Y; Shen, H; Sun, L; Wang, G; Wang, H; Wang, M; Wang, Y; Xiao, W; Xie, R; Xu, D; Xu, H; Yang, X; Yao, Z; Yu, F; Zhang, J; Zhang, Z; Zhao, M; Zhao, Y; Zhou, Y; Zhu, P; Zuo, X, 2019)
"To evaluate the efficacy and safety of leflunomide in the treatment of proliferative lupus nephritis, a prospective multi-centre observational study was conducted."5.13Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study. ( Cai, GY; Chen, XM; Cui, TG; Hou, FF; Jiang, ZP; Li, YN; Lu, FM; Mei, CL; Ni, ZH; Qian, JQ; Wang, GB; Wang, HY; Wang, YH; Xu, FF; Yu, XQ; Zhang, FS; Zhao, MH; Zhao, XZ; Zhu, TY; Zou, WZ, 2008)
"To evaluate the clinical efficacy and safety of leflunomide as a new immunosuppressive medicine in lupus nephritis (LN) through a meta-analysis."4.91The Efficacy and Safety of Leflunomide for the Treatment of Lupus Nephritis in Chinese Patients: Systematic Review and Meta-Analysis. ( Cao, H; Chen, Z; Lin, J; Liu, L; Rao, Y; Yang, H; Zhang, X, 2015)
" In this model, we evaluated the role of leflunomide on the development of lupus nephritis in system autoimmunity."3.78Therapeutic effect of leflunomide on the development of experimental lupus nephritis in mice. ( He, C; Liu, S; Lu, X; Luo, P; Wu, M; Yan, Z; Yu, Y, 2012)
"To evaluate the clinical and pathological efficacy, and safety of leflunomide as a new immunosuppressive medicine in lupus nephritis (LN)."3.75The efficacy and safety of leflunomide therapy in lupus nephritis by repeat kidney biopsy. ( Jin, XM; Li, YN; Nie, YK; Sun, Y; Yu, HM; Zhang, FS, 2009)
"Leflunomide (LEF) is a selective inhibitor of de novo pyrimidine synthesis, currently used in the treatment of rheumatoid arthritis."2.71[Treatment of proliferative lupus nephritis with leflunomide and steroid: a prospective multi-center controlled clinical trial]. ( Bao, CD; Cai, GY; Chen, XM; Cui, TG; Hou, FF; Li, YN; Lu, FM; Mei, CL; Ni, ZH; Qian, JQ; Wang, GB; Wang, HY; Zhang, FS; Zhao, MH; Zhao, XZ; Zhu, TY; Zou, WZ, 2005)
"The paradigm of immunosuppressive treatment for lupus nephritis has evolved over the past few decades from corticosteroids alone to corticosteroids combined with cyclophosphamide."2.52Treatment of severe lupus nephritis: the new horizon. ( Chan, TM, 2015)
"The condition of refractory lupus nephritis (LN) negatively affects the prognosis and life expectancy of the patients, posing a challenge to manage in clinical."1.91Treatment of refractory lupus nephritis using leflunomide: A prospective study. ( Chen, X; Chen, Y; Li, M; Wang, L; Zeng, X; Zhang, F; Zhang, S; Zhao, Y, 2023)
"Episcleritis and scleritis are relatively rare ocular diseases, which are commonly associated with rheumatic diseases including systemic lupus erythematosus (SLE)."1.43[Clinical characteristics of 4 cases of scleritis associated with systemic lupus erythematosus]. ( Jia, Y; Miao, H; Wang, L; Yang, Y; Zhang, XY; Zhou, YS, 2016)

Research

Studies (14)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (28.57)29.6817
2010's8 (57.14)24.3611
2020's2 (14.29)2.80

Authors

AuthorsStudies
Fu, Q1
Wu, C1
Dai, M1
Wang, S2
Xu, J1
Dai, L1
Li, Z2
He, L1
Zhu, X1
Sun, L2
Lu, L1
Bao, C1
Zhang, S1
Chen, Y1
Chen, X1
Zhao, Y2
Zeng, X1
Zhang, F1
Wang, L3
Li, M1
Zhang, M1
Qi, C1
Zha, Y1
Chen, J2
Luo, P2
Sun, Z1
Wan, J1
Xing, C1
Jiang, G1
Sun, M1
Chen, Q1
Li, D1
Guan, T1
Ni, Z1
An, Y2
Zhou, Y1
Bi, L1
Liu, B1
Wang, H1
Lin, J2
Xu, D1
Wang, M1
Zhang, J1
Wang, Y2
Zhu, P1
Xie, R1
Zhang, Z2
Mei, Y1
Liu, X1
Deng, X1
Yao, Z1
Xiao, W1
Shen, H1
Yang, X1
Xu, H1
Yu, F1
Wang, G1
Lu, X2
Li, Y3
Zuo, X1
Liu, Y1
Guo, J1
Zhao, M1
Chan, TM1
Hu, WX1
Chen, YH1
Bao, H1
Liu, ZZ1
Wang, SF1
Zhang, HT1
Liu, ZH1
Furie, R1
Toder, K1
Zapantis, E1
Cao, H1
Rao, Y1
Liu, L1
Yang, H1
Zhang, X1
Chen, Z1
Yang, Y1
Jia, Y1
Miao, H1
Zhou, YS1
Zhang, XY1
Wang, HY2
Cui, TG2
Hou, FF2
Ni, ZH2
Chen, XM2
Lu, FM2
Xu, FF1
Yu, XQ1
Zhang, FS3
Zhao, XZ2
Zhao, MH2
Wang, GB2
Qian, JQ2
Cai, GY2
Zhu, TY2
Wang, YH1
Jiang, ZP1
Li, YN3
Mei, CL2
Zou, WZ2
Nie, YK1
Jin, XM1
Yu, HM1
Sun, Y1
He, C1
Yan, Z1
Wu, M1
Liu, S1
Yu, Y1
Bao, CD1
Tam, LS1
Li, EK1
Wong, CK1
Lam, CW1
Li, WC1
Szeto, CC1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized Multicenter Trial Comparing Leflunomide and Azathioprine as Remission-Maintaining Treatment for Proliferative Lupus Glomerulonephritis.[NCT01172002]200 participants (Anticipated)Interventional2010-03-31Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

3 reviews available for leflunomide and Glomerulonephritis, Lupus

ArticleYear
Treatment of severe lupus nephritis: the new horizon.
    Nature reviews. Nephrology, 2015, Volume: 11, Issue:1

    Topics: Antimalarials; Azathioprine; Biological Products; Cyclophosphamide; Cyclosporine; Humans; Immunosupp

2015
Lessons Learned From the Clinical Trials of Novel Biologics and Small Molecules in Lupus Nephritis.
    Seminars in nephrology, 2015, Volume: 35, Issue:5

    Topics: Abatacept; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biological Products; Boron Com

2015
The Efficacy and Safety of Leflunomide for the Treatment of Lupus Nephritis in Chinese Patients: Systematic Review and Meta-Analysis.
    PloS one, 2015, Volume: 10, Issue:12

    Topics: Adult; Asian People; Cyclophosphamide; Female; Humans; Isoxazoles; Leflunomide; Lupus Nephritis; Mal

2015

Trials

6 trials available for leflunomide and Glomerulonephritis, Lupus

ArticleYear
Leflunomide versus azathioprine for maintenance therapy of lupus nephritis: a prospective, multicentre, randomised trial and long-term follow-up.
    Annals of the rheumatic diseases, 2022, Volume: 81, Issue:11

    Topics: Adult; Azathioprine; Creatinine; Cyclophosphamide; Drug Therapy, Combination; Follow-Up Studies; Hum

2022
Leflunomide versus cyclophosphamide in the induction treatment of proliferative lupus nephritis in Chinese patients: a randomized trial.
    Clinical rheumatology, 2019, Volume: 38, Issue:3

    Topics: Adult; Antibodies, Antinuclear; China; Complement C3; Cyclophosphamide; DNA; Drug Therapy, Combinati

2019
Combined immunosuppressive treatment (CIST) in lupus nephritis: a multicenter, randomized controlled study.
    Clinical rheumatology, 2019, Volume: 38, Issue:4

    Topics: Adult; Azathioprine; Cyclophosphamide; Drug Therapy, Combination; Female; Glucocorticoids; Humans; I

2019
Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study.
    Lupus, 2008, Volume: 17, Issue:7

    Topics: Adolescent; Adult; Aged; Biopsy; Disease Progression; Female; Humans; Immunosuppressive Agents; Isox

2008
[Treatment of proliferative lupus nephritis with leflunomide and steroid: a prospective multi-center controlled clinical trial].
    Zhonghua nei ke za zhi, 2005, Volume: 44, Issue:9

    Topics: Adolescent; Adult; Cyclophosphamide; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Imm

2005
Safety and efficacy of leflunomide in the treatment of lupus nephritis refractory or intolerant to traditional immunosuppressive therapy: an open label trial.
    Annals of the rheumatic diseases, 2006, Volume: 65, Issue:3

    Topics: Adult; Female; Humans; Immunosuppressive Agents; Isoxazoles; Leflunomide; Lupus Nephritis; Male; Mid

2006

Other Studies

5 other studies available for leflunomide and Glomerulonephritis, Lupus

ArticleYear
Treatment of refractory lupus nephritis using leflunomide: A prospective study.
    Frontiers in immunology, 2023, Volume: 14

    Topics: Cyclophosphamide; Humans; Leflunomide; Lupus Nephritis; Prospective Studies; Treatment Outcome

2023
Glucocorticoid with or without additional immunosuppressant therapy for patients with lupus podocytopathy: a retrospective single-center study.
    Lupus, 2015, Volume: 24, Issue:10

    Topics: Adolescent; Adult; Azathioprine; Cyclophosphamide; Drug Therapy, Combination; Female; Follow-Up Stud

2015
[Clinical characteristics of 4 cases of scleritis associated with systemic lupus erythematosus].
    Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences, 2016, 12-18, Volume: 48, Issue:6

    Topics: Adrenal Cortex Hormones; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Antinucle

2016
The efficacy and safety of leflunomide therapy in lupus nephritis by repeat kidney biopsy.
    Rheumatology international, 2009, Volume: 29, Issue:11

    Topics: Adolescent; Adult; Biopsy; Female; Humans; Immunosuppressive Agents; Isoxazoles; Kidney; Leflunomide

2009
Therapeutic effect of leflunomide on the development of experimental lupus nephritis in mice.
    Rheumatology international, 2012, Volume: 32, Issue:3

    Topics: Animals; Antigen-Antibody Complex; Ascites; Cell Proliferation; Disease Models, Animal; Female; Graf

2012